Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Randomized, Open-label Study of MK-1045 in Combination With Rituximab in Participants With 1L Follicular Lymphoma

NCT07634471 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT07634471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07634471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Randomized, Open-label Study of MK-1045 in Combination With Rituximab in Participants With 1L Follicular Lymphoma
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 2/3
Overall status
Recruiting
Start date
June 22, 2026
Completion date
July 23, 2035
Enrollment
960 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma